BOSTON, Feb. 5, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced it has demonstrated, in collaboration with OpenAI, an AI system that autonomously designed, executed, and learned from biological experiments with minimal human involvement. In a new preprint, the company reports the system reduced cell-free protein synthesis reaction costs by 40% relative to state of the art, while running 36,000 experimental conditions across six iterative cycles. Continue Reading Ginkgo's cloud lab in Boston ...

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) experienced a decline of 5.92% in its latest trading session, closing at $8.27, which underperformed compared to the S&P 500's loss of 0.51% [1] - Over the past month, the company's shares have decreased by 4.14%, lagging behind the Medical sector's gain of 3.1% and the S&P 500's increase of 0.93% [1] Upcoming Earnings - Analysts anticipate that Ginkgo Bioworks will report earnings of -$1.8 per share, indicating a year-over-year growth of 1.1%. Revenue is projected to be $37 million, reflecting a 15.62% decline from the same quarter last year [2] - For the full year, the Zacks Consensus Estimates predict earnings of -$5.94 per share and revenue of $173 million, representing changes of +42.66% in earnings and 0% in revenue compared to the previous year [3] Analyst Estimates and Rankings - Recent changes to analyst estimates for Ginkgo Bioworks are important as they reflect short-term business trends, with positive revisions indicating a favorable business outlook [4] - The Zacks Rank system, which incorporates these estimate changes, currently assigns Ginkgo Bioworks a rank of 3 (Hold), with the consensus EPS estimate remaining steady over the past month [6] Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which holds a Zacks Industry Rank of 90, placing it in the top 37% of over 250 industries [7] - Research indicates that industries in the top 50% outperform those in the bottom half by a factor of 2 to 1 [7]

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.31, reflecting a -1.27% change from the previous day, underperforming the S&P 500 which had a daily loss of 0.13% [1] - Over the last month, the company's shares increased by 13.48%, outperforming the Medical sector's decline of 2.41% and the S&P 500's gain of 0.78% [1] Earnings Estimates - The upcoming earnings release is anticipated, with an expected EPS of -$1.8, indicating a 1.1% growth compared to the same quarter last year [2] - Revenue is projected at $37 million, reflecting a 15.62% decrease from the equivalent quarter last year [2] - For the full year, earnings are estimated at -$5.94 per share and revenue at $173 million, showing a 42.66% increase in earnings but no change in revenue from the previous year [3] Analyst Sentiment - Recent changes to analyst estimates are crucial for investors, as they reflect short-term business trends and can indicate analyst optimism regarding profitability [3] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks Ginkgo Bioworks Holdings, Inc. at 3 (Hold) [5] Industry Context - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 90, placing it in the top 37% of over 250 industries [6] - The Zacks Industry Rank assesses the strength of industry groups based on the average Zacks Rank of individual stocks, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [6]

Company Performance - Ginkgo Bioworks Holdings, Inc. closed at $10.02, reflecting a -6.36% change from the previous day, underperforming the S&P 500's 0.03% gain [1] - Over the past month, shares of Ginkgo Bioworks have increased by 20.09%, outperforming the Medical sector's loss of 0.01% and the S&P 500's gain of 0.6% [1] Earnings Expectations - Analysts expect Ginkgo Bioworks to report earnings of -$1.8 per share, indicating a year-over-year growth of 1.1% [2] - The consensus estimate for revenue is $37 million, representing a 15.62% decrease compared to the same quarter of the previous year [2] Annual Forecast - For the entire year, Zacks Consensus Estimates predict earnings of -$5.94 per share and revenue of $173 million, showing changes of +42.66% and 0%, respectively, compared to the previous year [3] Analyst Sentiment - Recent changes to analyst estimates for Ginkgo Bioworks reflect evolving short-term business trends, with upward revisions indicating analysts' positive outlook on the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Ginkgo Bioworks as 3 (Hold) [6] Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which ranks in the top 36% of all industries according to the Zacks Industry Rank [7] - The Zacks Industry Rank assesses the strength of industry groups, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [7]

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.85, reflecting a +2.39% change from the previous day, outperforming the S&P 500's daily loss of 0.53% [1] - Over the past month, the company's shares have gained 16.47%, significantly exceeding the Medical sector's gain of 0.09% and the S&P 500's gain of 2.06% [1] Earnings Projections - The upcoming earnings disclosure is projected to show earnings per share (EPS) of -$1.8, which is a 1.1% increase from the same quarter last year [2] - Revenue is anticipated to be $37 million, indicating a 15.62% decrease from the same quarter last year [2] Full-Year Estimates - The full-year Zacks Consensus Estimates predict earnings of -$5.94 per share and revenue of $173 million, representing year-over-year changes of +42.66% for earnings and 0% for revenue [3] - Recent changes to analyst estimates for Ginkgo Bioworks should be monitored as they reflect evolving short-term business trends [3] Zacks Rank and Industry Performance - Ginkgo Bioworks currently holds a Zacks Rank of 3 (Hold), with no changes in the Zacks Consensus EPS estimate over the past month [5] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 96, placing it in the top 40% of over 250 industries [6]

Core Insights - MySize, Inc. is evaluating new opportunities to monetize its portfolio of aggregated and anonymized data intelligence assets in a responsible manner [1] Data Intelligence Insights - MySize's platforms have generated large-scale, privacy-compliant insights related to apparel fit trends, sizing mismatches, and product-level performance across brands and retailers, derived exclusively from anonymized and aggregated data [2] - The company is developing a secure Data Intelligence Framework to provide brands, manufacturers, and industry partners with access to insights that support demand planning, inventory optimization, customer trends, product design, and sustainability initiatives [3] Business Model Exploration - MySize is assessing usage-based digital access models, such as data credits, allowing enterprise customers to consume insights in a controlled, transparent, and scalable manner, built with a privacy-first approach and in compliance with data protection regulations like GDPR and CCPA [4] - The initiative remains in an exploratory phase, with no assurance regarding the timing, scope, or potential financial impact of future commercialization [5]

BOSTON, Jan. 13, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 10:30 a.m. PT (1:30 p.m. ET). Further details, including slides, will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events. About Ginkgo Bioworks Ginkgo Bioworks Contacts: INVESTOR CONTACT: [email protected] MEDIA CONTACT: [email protec ...

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) experienced a stock increase of +1.96% to $8.31, outperforming the S&P 500's daily loss of 0.74% [1] - Over the past month, the company's shares have declined by 5.12%, which is worse than the Medical sector's loss of 0.8% and the S&P 500's gain of 0.79% [1] Upcoming Earnings - The upcoming earnings release is anticipated to show an EPS of -$1.8, reflecting a 1.1% increase from the same quarter last year [2] - Revenue is forecasted at $37 million, indicating a 15.62% decrease compared to the same quarter last year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at -$5.94 per share, representing a 42.66% increase from the previous year [3] - Revenue for the fiscal year is estimated at $173 million, showing a 23.8% decline from the prior year [3] Analyst Estimates - Recent changes in analyst estimates for Ginkgo Bioworks are crucial as they reflect the evolving business trends [4] - Positive revisions in estimates are seen as indicators of analysts' confidence in the company's performance and profit potential [4] Zacks Rank and Industry Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently places Ginkgo Bioworks at 3 (Hold) [6] - The Medical - Biomedical and Genetics industry, which includes Ginkgo Bioworks, holds a Zacks Industry Rank of 92, placing it in the top 38% of over 250 industries [7]

Core Insights - Ginkgo Bioworks has partnered with Carnegie-Mellon University for the POSEIDON program, aimed at early cancer detection and intervention, supported by funding from ARPA-H [1][2] Group 1: Partnership and Project Overview - The partnership involves Ginkgo Bioworks as the Commercial Partner, with the project led by Rebecca Taylor from Carnegie Mellon University [1] - The project aims to develop an innovative orally administered pill with tumor-targeting sensors and a user-friendly at-home cancer screening device [2] Group 2: Technology and Innovation - The pill will utilize synthetic biology and nucleic acid nanotechnology to detect tumor-specific conditions such as low oxygen, acidity, and lactate, which are indicators of cancer [3] - The sensors will release reporters to indicate tumor presence and its tissue of origin, with results collected through urine [3] Group 3: Project Goals and Impact - The dual-function approach aims to provide high precision in detecting hidden tumors, potentially transforming early cancer diagnostics [4] - The project includes a multidisciplinary team from various academic institutions and corporate partners, emphasizing the importance of interdisciplinary collaboration in developing new diagnostics [4]

Core Insights - Thermo Fisher Scientific Inc. has launched two new products, Gibco™ Bacto™ CD Supreme FPM Plus and Gibco™ Bacto™ CD Supreme Feed (2X), aimed at enhancing plasmid DNA and recombinant protein production using E. coli [1] Product Launch - The new formulations are part of the Gibco™ Bacto™ CD portfolio, designed to simplify and improve the production processes for plasmid DNA and recombinant proteins [1] - The launch responds to the increasing demand for plasmid DNA, which is driven by the growth in gene therapy and mRNA vaccine development [1]